David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Stephen J. Schuster, MD, of the University of Pennsylvania, discusses the findings of a study of chimeric antigen receptor modified T cells directed against CD19 in patients with relapsed or refractory disease (Abstract 183).

Lymphoma

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and John F. Gerecitano, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss a phase I study of venetoclax monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma, including updated safety and efficacy data (Abstract 254).

Leukemia

Sébastien Maury, MD

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study

Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1). To see the French language version of this newsreel, please click here.

David A. Williams, MD

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Lymphoma

Craig H. Moskowitz, MD

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Craig H. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center, discusses a phase I study of an anti-CD19 monoclonal antibody used in relapsed/refactory B-lineage non-Hodgkin lymphoma (Abstract 182).

Jul

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Stephen J. Schuster, MD, on CD19+ Lymphomas: Sustained Remissions in Relapsed or Refractory Disease

Julie Vose, MD, MBA, and John F. Gerecitano, MD, PhD, on Venetoclax for NHL

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Craig H. Moskowitz, MD, on NHL: Early Study Results on Denintuzumab Mafodotin

Metastatic Castration-Resistant Prostate Cancer Comparison of Second-Line Regimens

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

HER3-DXd in NSCLC Without EGFR-Activating Mutations

Survey Shows Inaccuracies in US Perceptions of Testicular Cancer

utDNA May Help to Personalize Bladder Cancer Treatment